Stem cells are used in regenerative medicine to repair, replace, or restore damaged tissues across a growing range of conditions, from arthritic joints to failing hearts to diabetic wounds that won’t heal. Some applications are already approved and routine, while others are showing striking results in clinical trials. The field has also shifted in a surprising way: much of the benefit from stem cells comes not from the cells themselves turning into new tissue, but from the chemical signals they release into their surroundings.
How Stem Cells Actually Repair Tissue
The early promise of stem cells was straightforward: inject cells that can become anything, and they’ll replace whatever tissue is damaged. Reality turned out to be more nuanced. Stem cells contribute to repair largely through what scientists call paracrine signaling. They release a complex mix of proteins and growth factors into surrounding tissue that kick-start the body’s own healing processes. These signals promote new blood vessel formation, reduce cell death, calm inflammation, and stimulate local cells to begin rebuilding.
Mesenchymal stem cells (MSCs), one of the most widely studied types, secrete high levels of factors that drive new blood vessel growth and protect injured tissue from further damage. This means that even when transplanted stem cells don’t permanently engraft or survive long-term, they can still leave lasting benefits by reprogramming the local environment during a critical window of healing. Some stem cell therapies do work by direct replacement, particularly newer approaches that transplant fully differentiated cells like insulin-producing islet cells or retinal cells. But the paracrine effect remains central to many applications.
Types of Stem Cells in Clinical Use
Three main categories of stem cells drive current regenerative medicine. Adult stem cells, particularly MSCs harvested from bone marrow or fat tissue, are the most widely used in clinical trials. They’re relatively easy to obtain and can be sourced from the patient’s own body, which sidesteps immune rejection.
Embryonic stem cells can become virtually any cell type in the body, but their use requires destroying early-stage embryos, which made them ethically controversial and limited their clinical development. They also produce cells that are genetically foreign to the recipient, potentially requiring lifelong immune suppression.
Induced pluripotent stem cells (iPSCs) emerged as a workaround. Created by reprogramming a patient’s own adult cells back to a stem-like state, they share the versatility of embryonic stem cells without the ethical concerns or immune barriers. Despite early questions about whether iPSCs were truly equivalent to embryonic stem cells, recent evidence shows the two are largely indistinguishable, with most differences traced to normal genetic variation between donors rather than the reprogramming process itself. Cord blood stem cells round out the picture. The FDA has approved several cord blood products for clinical use, primarily for blood and immune system disorders.
Joint and Cartilage Repair
Osteoarthritis is one of the most active areas of stem cell research, driven by the fact that cartilage has almost no ability to repair itself. Standard treatments manage symptoms but don’t reverse damage, and only about 50% of patients with moderate to severe disease heal adequately within 20 weeks using conventional approaches.
Clinical trials using MSC injections directly into arthritic joints have shown meaningful improvements in pain and function. In one trial comparing bone marrow-derived MSCs to hyaluronic acid (a standard injection therapy), patients receiving stem cells reported better pain scores and functional outcomes that held up over four years of follow-up, with the high-dose group showing the greatest benefit. A study using umbilical cord-derived MSCs in 36 patients with moderate to severe knee osteoarthritis found that two monthly injections produced better pain, function, and quality-of-life scores than the control group at six months.
Interestingly, dose doesn’t always follow a “more is better” pattern. A trial testing fat-derived MSCs at three different doses found that the lowest dose, just 2 million cells, produced significant pain relief and functional improvement at six months. This may reflect the paracrine mechanism: a smaller number of cells can still release enough healing signals to shift the local environment.
Heart Failure and Cardiac Repair
After a heart attack, damaged muscle is replaced by scar tissue that can’t pump blood. Stem cell therapy aimed to reverse this, and early results generated enormous excitement. The picture that has emerged over two decades of trials is more measured.
A large meta-analysis found that bone marrow-derived MSCs improved the heart’s pumping efficiency (left ventricular ejection fraction) by about 3 to 6 percentage points in several reviews, a result that was statistically significant but considered clinically modest. One analysis of 48 studies found an average improvement of about 3%, while another reported a roughly 6% gain along with a meaningful increase in how far patients could walk in six minutes (about 28 meters farther). However, a more recent meta-analysis focused specifically on patients with reduced heart function found that MSC therapy produced only a small, non-significant improvement.
The takeaway is that stem cells for heart failure haven’t delivered the dramatic reversal once hoped for, but they do appear to offer a modest benefit for some patients, potentially by protecting surviving heart muscle and encouraging new blood vessel growth rather than regenerating large amounts of new cardiac tissue.
Replacing Insulin-Producing Cells in Diabetes
Type 1 diabetes destroys the insulin-producing islet cells of the pancreas, forcing patients into lifelong insulin dependence. Replacing those cells with stem cell-derived islets represents one of the most concrete successes in regenerative medicine to date.
A trial published in the New England Journal of Medicine tested fully differentiated islet cells grown from stem cells in 12 participants with type 1 diabetes. By day 365, 10 of 12 participants (83%) had achieved insulin independence, meaning they no longer needed insulin injections. That result is remarkable for a disease that currently has no cure, and it represents a shift from managing symptoms to restoring the body’s own function.
Restoring Vision in Macular Degeneration
Age-related macular degeneration (AMD) destroys the retinal pigment epithelium, a thin layer of cells behind the retina essential for vision. Once these cells are gone, vision loss is progressive and irreversible with current treatments. Stem cell-derived replacements for this cell layer are now in early human trials.
A first-in-human trial transplanted 50,000 stem cell-derived retinal pigment cells under the macula of patients with dry AMD. Patients with the worst baseline vision (20/200 to 20/800) gained an average of nearly 22 letters on a standard eye chart at 12 months, a substantial improvement. To put that in perspective, their untreated eyes lost about 1 to 2 letters over the same period, making the net difference between treated and untreated eyes roughly 23 letters at one year. Patients who started with better vision showed more modest gains of about 3 to 4 letters, likely because they had less room to improve. Vision improvements appeared within one to four weeks after transplantation, consistent with the cells engrafting and beginning to function.
Rebuilding Neurons in Parkinson’s Disease
Parkinson’s disease is caused by the progressive loss of dopamine-producing neurons in the brain. A phase I trial tested transplantation of dopamine neuron precursors derived from human embryonic stem cells directly into the brains of patients with Parkinson’s. The trial met its primary safety goals, with no adverse events related to the cell product at one year. Brain imaging at 18 months confirmed the grafted cells had survived and were producing dopamine. Patients in the high-dose group improved by an average of 23 points on a standard Parkinson’s motor scale when assessed without medication, a notable change in daily function. These are early-phase results in a small group, but they provide the first human evidence that lab-grown neurons can survive, integrate, and function in the Parkinsonian brain.
Healing Chronic Diabetic Wounds
Diabetic foot ulcers are notoriously difficult to heal. About 20% of moderate to severe cases end in amputation, and even with standard care, half of patients don’t heal within 20 weeks while half of those who do heal see their wounds return within 18 months. Stem cell therapies are showing the potential to dramatically improve those numbers.
In one study, a stem cell-containing hydrogel applied to diabetic foot ulcers decreased wound size within three weeks and promoted thick new tissue growth, avoiding amputation entirely. Another trial found that stem cells combined with a nanofiber scaffold reduced wound size by 66%, and adding platelet-rich plasma pushed that to 71%, compared to just 36% wound reduction in the control group. A larger study of stem cell-treated wounds reported that 93% of patients (50 out of 54) achieved full wound closure by 12 months, and the remaining four patients still reached at least 85% closure.
Where Things Stand Now
The gap between what’s proven and what’s marketed remains wide. The FDA has approved a handful of stem cell products, mostly cord blood therapies for blood disorders and one MSC product. Hundreds of clinics offer unapproved “stem cell treatments” for everything from wrinkles to autism, often with no clinical evidence behind them. The legitimate science, meanwhile, is producing genuinely transformative results in specific areas: insulin independence for type 1 diabetes, meaningful vision restoration in macular degeneration, and functional improvement in Parkinson’s disease. The field has matured past the idea that stem cells are a universal fix and toward precision applications where the right cell type, delivered to the right tissue, can restore a specific lost function.